Structured medication reviews in Parkinson's disease: pharmacists' views, experiences and needs - a qualitative study.

Background: Executing structured medication reviews (SMRs) in primary care to optimize drug treatment is considered standard care of community pharmacists in the Netherlands. Patients with Parkinson's disease (PD) often face complex drug regimens for their symptomatic treatment and might, therefore, benefit from an SMR. However, previously, no effect of an SMR on quality of life in PD was found.

Cost-utility analysis of a structured medication review compared to usual care in Parkinson's disease.

Purpose: For controlling symptoms in Parkinson's disease (PD) together with treating additional comorbidities, patients often face complex medication regimens, with suboptimal adherence, drug-related problems, and diminished therapy efficacy as a common consequence. A medication review could potentially tackle these issues, among others by optimizing drug treatment. Even if no change in clinical outcomes is observed, this intervention might decrease health care costs by reducing drug-related problems and hospital admissions.

The Effect of a Structured Medication Review on Quality of Life in Parkinson's Disease.

Background: Drug therapy is important for controlling symptoms in Parkinson's disease (PD). However, it often results in complex medication regimens and could easily lead to drug related problems (DRP), suboptimal adherence and reduced treatment efficacy. A structured medication review (SMR) could address these issues and optimize therapy, although little is known about clinical effects in PD patients.

SARS-CoV-2 vaccine-related neurological complications.

Objective: To describe three cases with neurological symptoms after SARS-CoV-2 vaccination.

Methods: A case series followed by a review of the literature, describing hypotheses on how neurological symptoms might develop after vaccination.

Results: The different temporal relationship between the onset or worsening of different neurological symptoms suggests different pathophysiological mechanisms.

The Impact of Non-dopaminergic Medication on Quality of Life in Parkinson's Disease.

Background And Objectives: Quality of life (QoL) in Parkinson's disease (PD) depends on multiple factors. Due to PD treatment and accompanying, age-related or independent comorbidities, pill burden is often high. The relation of QoL and pharmacotherapy for comorbidities in PD has not been widely studied.